PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b to Treat Essential Thrombocythemia
With a diversifying pipeline, the company is evaluating applications for pegylated interferon to address underserved hematologic cancers BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia…